Table 2.
Baseline demographic and clinical characteristics of the whole study population, participants taking MAO-B inhibitors at baseline and those who were treatment-naive at baseline
| Whole population | MAO-B inhibitors | Treatment-naive | ||||
|---|---|---|---|---|---|---|
| Placebo (n = 105) | Prasinezumab pooled (n = 211) | Placebo (n = 38) | Prasinezumab pooled (n = 77) | Placebo (n = 67) | Prasinezumab pooled (n = 134) | |
| Age (years), mean (s.d.) | 59.9 (8.7) | 59.9 (9.3) | 58.3 (8.4) | 58.2 (9.4) | 60.8 (8.8) | 60.9 (9.2) |
| Sex (male), n (%) | 71 (67.6) | 142 (67.3) | 24 (63.2) | 50 (64.9) | 47 (70.1) | 92 (68.7) |
| Time since diagnosis (months), mean (s.d.) | 9.95 (6.79) | 10.19 (6.37) | 11.93 (6.37) | 11.98 (5.99) | 8.83 (6.81) | 9.17 (6.37) |
| Time since diagnosis ≤12 months, n (%) | 72 (68.6) | 147 (69.7) | 22 (57.9) | 47 (61.0) | 50 (74.6) | 100 (74.6) |
| Hoehn and Yahr stage, n (%) | ||||||
| Stage I | 20 (19.0) | 58 (27.5) | 7 (18.4) | 25 (32.5) | 13 (19.4) | 33 (24.6) |
| Stage II | 85 (81.0) | 153 (72.5) | 31 (81.6) | 52 (67.5) | 54 (80.6) | 101 (75.4) |
| MDS-UPDRS total (sum of Parts I, II and III), mean (s.d.) | 32.01 (12.98) | 31.11 (12.70) | 32.16 (12.01) | 29.25 (11.90) | 31.93 (13.58) | 32.19 (13.06) |
| MDS-UPDRS Part I, mean (s.d.) | 4.91 (3.71) | 4.45 (3.88) | 5.08 (3.82) | 4.19 (3.15) | 4.82 (3.67) | 4.60 (4.25) |
| MDS-UPDRS Part II, mean (s.d.) | 5.55 (4.09) | 5.22 (4.03) | 5.84 (4.25) | 4.87 (3.69) | 5.39 (4.01) | 5.43 (4.21) |
| MDS-UPDRS Part III, mean (s.d.) | 21.54 (9.11) | 21.44 (8.97) | 21.24 (8.77) | 20.18 (8.87) | 21.72 (9.36) | 22.16 (8.98) |
| DaT-SPECT SBRa, mean (s.d.) | 1.06 (0.30) | 1.06 (0.34) | 1.03 (0.30) | 1.02 (0.31) | 1.09 (0.29) | 1.09 (0.35) |
| Estimated average change in MDS-UPDRS Part III per month before the study (points per month) | 2.16 | 2.10 | 1.78 | 1.68 | 2.46 | 2.42 |
n is the number of participants contributing to summary statistics. Percentages are based on n.
aIpsilateral putamen. DaT-SPECT, dopamine transporter-single-photon emission computed tomography; MAO-B, monoamine oxidase-B; MDS-UPDRS, Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; s.d., standard deviation; SBR, striatal binding ratio.